HK1216720A1 - 用於递送治疗剂的可生物蚀解的硅基组合物 - Google Patents

用於递送治疗剂的可生物蚀解的硅基组合物 Download PDF

Info

Publication number
HK1216720A1
HK1216720A1 HK16104751.3A HK16104751A HK1216720A1 HK 1216720 A1 HK1216720 A1 HK 1216720A1 HK 16104751 A HK16104751 A HK 16104751A HK 1216720 A1 HK1216720 A1 HK 1216720A1
Authority
HK
Hong Kong
Prior art keywords
composition
carrier material
therapeutic agent
biomolecule
certain embodiments
Prior art date
Application number
HK16104751.3A
Other languages
English (en)
Chinese (zh)
Inventor
．巴奈特
C．巴奈特
．阿什通
P．阿什通
．坎漢
L．T．坎汉
Original Assignee
Psi医疗有限公司
视点制药美国有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psi医疗有限公司, 视点制药美国有限公司 filed Critical Psi医疗有限公司
Publication of HK1216720A1 publication Critical patent/HK1216720A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16104751.3A 2013-03-15 2014-03-13 用於递送治疗剂的可生物蚀解的硅基组合物 HK1216720A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361798324P 2013-03-15 2013-03-15
US61/798,324 2013-03-15
PCT/US2014/025612 WO2014151381A1 (en) 2013-03-15 2014-03-13 Bioerodible silicon-based compositions for delivery of therapeutic agents

Publications (1)

Publication Number Publication Date
HK1216720A1 true HK1216720A1 (zh) 2016-12-02

Family

ID=51528085

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16104751.3A HK1216720A1 (zh) 2013-03-15 2014-03-13 用於递送治疗剂的可生物蚀解的硅基组合物

Country Status (9)

Country Link
US (2) US9603801B2 (enExample)
EP (1) EP2968571A4 (enExample)
JP (1) JP2016512839A (enExample)
CN (1) CN105025928A (enExample)
AU (1) AU2014235051B2 (enExample)
CA (1) CA2904077A1 (enExample)
HK (1) HK1216720A1 (enExample)
RU (1) RU2705986C2 (enExample)
WO (1) WO2014151381A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968571A4 (en) * 2013-03-15 2016-09-07 Psivida Inc BIODEGRADABLE SILICONE BASED COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS
KR20230042391A (ko) 2014-10-03 2023-03-28 나노틱스 엘엘씨 가용성 생물분자의 생물학적 활성을 억제하기 위한 조성물 및 방법
WO2017176762A1 (en) 2016-04-06 2017-10-12 Nanotics, Llc Particles comprising subparticles or nucleic acid scaffolds
US20210121534A1 (en) 2018-06-19 2021-04-29 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
JP2021531328A (ja) 2018-06-19 2021-11-18 セラ セラピューティクス エルエルシー 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ−α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン−アスパラギン酸プロテアーゼを含む薬剤送達系
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
US11458092B2 (en) 2018-12-14 2022-10-04 NuVessl, Inc. Composition with enhanced passenger molecule loading
EP3714879A1 (en) 2019-03-28 2020-09-30 Sisaf Ltd Structured encapsulated silicon-containing particles
GB201904336D0 (en) 2019-03-28 2019-05-15 Sisaf Ltd A delivery system
GB201904334D0 (en) * 2019-03-28 2019-05-15 Sisaf Ltd Carrier system for preparing herbaceous extracts
CN114948864A (zh) * 2021-02-26 2022-08-30 奈力生医股份有限公司 用于将药剂递送到眼后段的方法和其用途

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3832458A (en) 1971-12-06 1974-08-27 River C Foundation Hydrophilic silicone composition and method
US4036979A (en) 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
US3919723A (en) 1974-05-20 1975-11-18 Friedrichsfeld Gmbh Bone shaft or bone joint prosthesis and process
US3919060A (en) 1974-06-14 1975-11-11 Ibm Method of fabricating semiconductor device embodying dielectric isolation
DE3214667C2 (de) 1982-04-21 1985-07-18 Akzo Gmbh, 5600 Wuppertal Zusammengesetzter Körper für die Langzeitabgabe von Wirkstoffen
JPS59101145A (ja) 1982-11-30 1984-06-11 日本特殊陶業株式会社 薬液含浸多孔質セラミツクス
JPS59131346A (ja) 1983-01-17 1984-07-28 日本特殊陶業株式会社 薬液含浸多孔質セラミツクスの製造法
DE3423667A1 (de) 1984-05-08 1985-11-28 Rüdiger Dipl.-Ing. 5204 Lohmar Scheunemann Implantat fuer knochen- und zahnwurzelersatz mit spezieller uebergangsstruktur zwischen knochen und implantatkern und knochenseitig ganz oder teilweise resorbierbarer matrix
GB8422876D0 (en) 1984-09-11 1984-10-17 Secr Defence Silicon implant devices
US4608048A (en) 1984-12-06 1986-08-26 Alza Corporation Dispensing device with drug delivery patterns
US5057082A (en) 1988-11-04 1991-10-15 Plastic Injectors, Inc. Trocar assembly
ATE90203T1 (de) 1989-03-17 1993-06-15 Pitman Moore Inc Kontrollierte, verzoegerte wirkstofffreisetzung von makromolekularen proteinen.
US5167625A (en) 1990-10-09 1992-12-01 Sarcos Group Multiple vesicle implantable drug delivery system
US5366454A (en) 1993-03-17 1994-11-22 La Corporation De L'ecole Polytechnique Implantable medication dispensing device
US5370630A (en) 1993-11-12 1994-12-06 Smidebush; Michael J. Device for injection of fluidic materials into body tissue
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US5558071A (en) 1994-03-07 1996-09-24 Combustion Electromagnetics, Inc. Ignition system power converter and controller
US5817327A (en) 1994-07-27 1998-10-06 The Trustees Of The University Of Pennsylvania Incorporation of biologically active molecules into bioactive glasses
US5591453A (en) 1994-07-27 1997-01-07 The Trustees Of The University Of Pennsylvania Incorporation of biologically active molecules into bioactive glasses
US5665114A (en) 1994-08-12 1997-09-09 Meadox Medicals, Inc. Tubular expanded polytetrafluoroethylene implantable prostheses
US5792099A (en) 1995-02-14 1998-08-11 Decamp; Dennis Syringe and cannula for insertion of viscoelastic material into an eye and method of using same
MX9707585A (es) 1995-04-03 1997-12-31 Abbott Lab Mezclas homogeneas de farmacos y aditivos de fusion a baja temperatura para liberacion controlada.
US6096344A (en) 1995-07-28 2000-08-01 Advanced Polymer Systems, Inc. Bioerodible porous compositions
GB9611437D0 (en) 1995-08-03 1996-08-07 Secr Defence Biomaterial
US5665428A (en) 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
DE19608423A1 (de) 1996-03-05 1997-09-11 Merck Patent Gmbh Implantate mit phasenweiser Arzneistoffabgabe
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US7070590B1 (en) 1996-07-02 2006-07-04 Massachusetts Institute Of Technology Microchip drug delivery devices
US5922299A (en) 1996-11-26 1999-07-13 Battelle Memorial Institute Mesoporous-silica films, fibers, and powders by evaporation
JP3217286B2 (ja) 1996-12-19 2001-10-09 科学技術振興事業団 Ｄｎａ固定化複合体
EP0913177A1 (de) * 1997-11-03 1999-05-06 Roche Diagnostics GmbH Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung
AU2460099A (en) * 1998-01-20 1999-08-02 Drexel University Mesoporous materials and methods of making the same
US6696258B1 (en) 1998-01-20 2004-02-24 Drexel University Mesoporous materials and methods of making the same
US6060036A (en) 1998-02-09 2000-05-09 Implant Sciences Corporation Radioactive seed implants
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
GB9815819D0 (en) 1998-07-22 1998-09-16 Secr Defence Transferring materials into cells and a microneedle array
IL143846A0 (en) 1998-12-23 2002-04-21 Alza Corp Dosage forms comprising porous particles
WO2001012221A1 (en) 1999-08-16 2001-02-22 Henceforth Hibernia, Inc. Therapeutic and prophylactic compositions including catalytic biomimetic solids and methods to prepare and use them
GB9924334D0 (en) 1999-10-15 1999-12-15 Secr Defence Pharmaceutical products and methods of fabrication therefor
CN1287859C (zh) 1999-10-18 2006-12-06 费克斯公司 定向递送生物活性剂的由铁和多孔材料构成的磁引导载体
SE9903958D0 (sv) 1999-11-02 1999-11-02 Boerje Sellergren Porous materials for selective binding or transport of molecular guests
US6521284B1 (en) 1999-11-03 2003-02-18 Scimed Life Systems, Inc. Process for impregnating a porous material with a cross-linkable composition
AUPQ573300A0 (en) 2000-02-21 2000-03-16 Australian Nuclear Science & Technology Organisation Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use
CZ298259B6 (cs) 2000-02-28 2007-08-08 Aventis Pharma S. A. Farmaceutická kombinace k lécení rakoviny obsahující CPT-11 a capecitabin
IL134830A0 (en) 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
WO2001068112A2 (en) 2000-03-14 2001-09-20 Goeke Burkhard Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
GB0008494D0 (en) 2000-04-07 2000-05-24 Secr Defence Microprojectile delivery system
GB2365769A (en) 2000-08-18 2002-02-27 Secr Defence Skin preparations containing silicon
GB0104383D0 (en) 2001-02-22 2001-04-11 Psimedica Ltd Cancer Treatment
WO2002096389A1 (en) 2001-05-30 2002-12-05 Microchips, Inc. Conformal coated microchip reservoir devices
JP2005536625A (ja) * 2002-08-23 2005-12-02 マクマスター ユニバーシティー ポリオール修飾シラン由来シリカの形態および収縮を制御する方法および化合物
PL223153B1 (pl) 2002-09-18 2016-10-31 Allergan Inc Urządzenie do wszczepiania implantu okulistycznego
WO2004071949A2 (en) 2003-02-13 2004-08-26 The Regents Of The University Of California Nanostructured casting of organic and bio-polymers in porous silicon templates
US7433811B2 (en) 2003-05-06 2008-10-07 The Regents Of The University Of California Direct patterning of silicon by photoelectrochemical etching
US7563451B2 (en) * 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
EP1677828B1 (en) 2003-10-21 2012-12-26 PSIMedica Limited Composite material comprising a porous semiconductor impregnated with an organic substance
GB0324483D0 (en) 2003-10-21 2003-11-19 Psi Medica Ltd Composite material
US20050181049A1 (en) 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
US7448867B2 (en) 2004-09-17 2008-11-11 Ormco Corporation Medical treatment apparatus
WO2006039333A1 (en) 2004-09-30 2006-04-13 Bausch & Lomb Incorporated Ophthalmic drug release device for multiple drug release
CA2583054A1 (en) 2004-10-05 2006-04-13 The University Of Melbourne Porous polyelectrolyte materials
EP1817003B1 (en) 2004-10-29 2018-02-21 The Regents of The University of California Porous silicon microparticles for drug delivery to the eye
JP4977475B2 (ja) 2004-12-21 2012-07-18 日本電気株式会社 フィルム外装電気デバイス用ケース
JP2007091716A (ja) 2005-08-29 2007-04-12 Kuraray Co Ltd 水中薬剤徐放性微粒子及びその製造方法
GB0526332D0 (en) 2005-12-23 2006-02-01 Psimedica Ltd Pharmaceutical product
EP1999247A4 (en) 2006-03-14 2011-08-31 Univ Rochester CELL CULTURAL DEVICES WITH ULTRADOOR POROUS MEMBRANE AND APPLICATIONS THEREOF
ES2640458T3 (es) 2006-03-31 2017-11-03 Mati Therapeutics Inc. Implantes del sistema de drenaje nasolagrimal para terapia medicamentosa
US20080057102A1 (en) 2006-08-21 2008-03-06 Wouter Roorda Methods of manufacturing medical devices for controlled drug release
BRPI0717171B1 (pt) 2006-09-25 2023-10-17 Archer Daniels Midland Company Material superabsorvente
JP5141948B2 (ja) 2007-07-09 2013-02-13 株式会社豊田中央研究所 バイモダルな細孔構造を有する球状シリカ系メソ多孔体及びその製造方法
KR20160021307A (ko) 2007-07-10 2016-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 선택된 조직에 조성물을 전달하는 물질 및 방법
US20130084243A1 (en) 2010-01-27 2013-04-04 Liliane Goetsch Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
WO2010036702A1 (en) 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
GB0817938D0 (en) 2008-09-30 2008-11-05 Intrinsiq Materials Global Ltd Cosmetic formulations
GB0817936D0 (en) 2008-09-30 2008-11-05 Intrinsiq Materials Global Ltd Porous materials
WO2010090596A1 (en) 2009-02-04 2010-08-12 Agency For Science, Technology And Research Hollow silica particle with a polymer thereon
US20110300222A1 (en) 2009-02-20 2011-12-08 The Regents Of The University Of California Luminescent porous silicon nanoparticles, methods of making and using same
US20100247607A1 (en) 2009-03-26 2010-09-30 Psivida Us, Inc. Implantable formulations of bisphosphonic acids
JP5382700B2 (ja) 2009-03-27 2014-01-08 独立行政法人産業技術総合研究所 ロッド状多孔質シリカ粒子
EP2427179A4 (en) 2009-05-04 2013-09-11 Psivida Inc POROUS SILICON MEDICATION ELUTING PARTICLES
US20110028412A1 (en) 2009-08-03 2011-02-03 Cappellos, Inc. Herbal enhanced analgesic formulations
DE102010008982A1 (de) * 2010-02-24 2011-08-25 Bayer Innovation GmbH, 40225 Siliciumhaltiges, biologisch degradierbares Material zur anti-inflammatorischen Therapie
GB201017048D0 (en) * 2010-10-08 2010-11-24 Ucl Business Plc Composition
CA2816576C (en) * 2010-11-01 2020-06-02 Psivida Us, Inc. Bioerodible silicon-based devices for delivery of therapeutic agents
WO2012088304A2 (en) 2010-12-22 2012-06-28 Psivida Us, Inc. Two-piece injectable drug delivery device with heat-cured seal
CA2827082A1 (en) 2011-02-11 2012-08-16 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics
CA2830654A1 (en) * 2011-03-31 2012-10-04 Galderma Research & Development Compositions comprising a filler product and at least one bioresorbable and biodegradable silica-based material
DK3290024T3 (da) 2011-08-29 2019-06-03 Mati Therapeutics Inc Vedvarende indgivelse af aktive midler til behandling af glaukom og okulær hypertension
WO2014165108A1 (en) * 2013-03-12 2014-10-09 Psivida Us, Inc. Bioerodible silicon-based delivery vehicles for delivery of therapeutic agents
EP2968571A4 (en) * 2013-03-15 2016-09-07 Psivida Inc BIODEGRADABLE SILICONE BASED COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS

Also Published As

Publication number Publication date
EP2968571A4 (en) 2016-09-07
US20140271886A1 (en) 2014-09-18
WO2014151381A1 (en) 2014-09-25
US20170049703A1 (en) 2017-02-23
AU2014235051A1 (en) 2015-08-20
JP2016512839A (ja) 2016-05-09
CN105025928A (zh) 2015-11-04
US9980911B2 (en) 2018-05-29
CA2904077A1 (en) 2014-09-25
AU2014235051B2 (en) 2019-01-17
RU2015132217A (ru) 2017-04-20
US9603801B2 (en) 2017-03-28
EP2968571A1 (en) 2016-01-20
RU2015132217A3 (enExample) 2018-03-22
RU2705986C2 (ru) 2019-11-13

Similar Documents

Publication Publication Date Title
US9980911B2 (en) Bioerodible silicon-based compositions for delivery of therapeutic agents
US9808421B2 (en) Bioerodible silicon-based devices for delivery of therapeutic agents
US20160346211A1 (en) Bioerodible silicon-based delivery vehicles for delivery of therapeutic agents
US8088401B2 (en) Composite material comprising a porous semiconductor impregnated with an organic substance
EP1677828B1 (en) Composite material comprising a porous semiconductor impregnated with an organic substance
US20160075776A1 (en) Compositions and Methods for Controlled Release of Agents
HK1188733B (en) Bioerodible silicon-based devices for delivery of therapeutic agents
HK1188733A (en) Bioerodible silicon-based devices for delivery of therapeutic agents